EE UU tiene millones de vacunas a punto de vencerse y no saben qué hacer con ellas lanacion.com.ar - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lanacion.com.ar Daily Mail and Mail on Sunday newspapers.
Acting Secretary of Health Alison Beam made the announcement Thursday during a media briefing. After reviewing the vaccination data for people 18 and over and discussing it with the COVID-19 Vaccine Legislative Task Force, we have determined that the commonwealth s mask order can safely be lifted on June 28 or when 70% of adults get their second dose, whichever comes first, Beam said.
- Advertisement -
According to the state Department of Health, 52.7% of adults age 18 and older have been fully vaccinated in the state. Based on this data, Beam said the state is on track to reach 70% of adults being fully vaccinated by the end of June.
La nominada trans de Biden por HHS elude las preguntas de Rand Paul sobre los cambios de sexo en los niños christianpost.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from christianpost.com Daily Mail and Mail on Sunday newspapers.
Date Time
Researchers Develop Potentially Safer, More Effective Gene Therapy Vector for Blood Disorders
Researchers at Children’s Hospital of Philadelphia (CHOP) have developed a gene therapy vector for blood disorders like sickle cell disease and beta-thalassemia that is potentially safer and more effective than those currently used in gene therapy trials for those conditions. The vector, an engineered vehicle for delivering functional copies of the hemoglobin gene to correct a genetic abnormality, leads to the production of more hemoglobin with a lower dose, minimizing the risk of toxic side effects.
The findings were published today in Molecular Therapy.
“These results have many potential benefits for the successful treatment of patients affected by beta-globinopathies like sickle cell disease and beta-thalassemia, including a better dose response, a minimized chance of clonal expansion and tumorigenesis, a reduced cost of therapy, and a potentially reduced need for chemot
E-Mail
Philadelphia, January 29, 2021 Researchers at Children s Hospital of Philadelphia (CHOP) have developed a gene therapy vector for blood disorders like sickle cell disease and beta-thalassemia that is potentially safer and more effective than those currently used in gene therapy trials for those conditions. The vector, an engineered vehicle for delivering functional copies of the hemoglobin gene to correct a genetic abnormality, leads to the production of more hemoglobin with a lower dose, minimizing the risk of toxic side effects.
The findings were published today in
Molecular Therapy. These results have many potential benefits for the successful treatment of patients affected by beta-globinopathies like sickle cell disease and beta-thalassemia, including a better dose response, a minimized chance of clonal expansion and tumorigenesis, a reduced cost of therapy, and a potentially reduced need for chemotherapy or radiation before beginning gene therapy, said Laura Bre